Clinical Trials of IBI3035 in Healthy Subjects

NCT07591519 | Not Yet Recruiting Phase 1

• 1 other identifier: CIBI3035A101CN
• Study Type: interventional
• Target: 144
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

Conditions

Healthy Person

Outcome Measures

Primary Outcomes (2)

• The area under the blood drug concentration-time curve from 0 to 168 hours

  From 0 to 168 hours after administration

• Area Under Curve Glucose Infusion Rate (AUCGIR) 0-168h

  From 0 to 168 hours after administration

Secondary Outcomes (17)

• Area Under Curve (AUC0-84h)

  From 0 to 84 hours after administration

• Tmax

  From 0 to 168 hours after administration

• Glucose Infusion Rate (GIR) max

  From 0 to 168 hours after administration

• Area Under Curve Glucose Infusion Rate (AUCGIR) 24-48h

  From 24 to 48 hours after administration

• Adverse events (AE)

  through study completion, an average of 16 weeks

Study Arms (2)

Insulin icodec Injection

ACTIVE COMPARATOR

The first cycle is Awiqli® 1 U/kg, and the second cycle is IBI3035 1 U/kg

Biological: IBI3035; Biological: Insulin icodec Injection

IBI3035

EXPERIMENTAL

The first cycle is IBI3035 1 U/kg, and the second cycle is Awiqli® 1 U/kg

Biological: IBI3035; Biological: Insulin icodec Injection

Interventions

IBI3035 BIOLOGICAL

IBI3035 administered subcutaneously(SC)

IBI3035; Insulin icodec Injection

Insulin icodec Injection BIOLOGICAL

Insulin icodec Injection administered subcutaneously(SC)

IBI3035; Insulin icodec Injection

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: Male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male adult subjects aged 18 to 45 years (including 18 and 45 years, based on the date of signing the informed consent form) of Chinese nationality;
• Body Mass Index (BMI) between 19.0 and 24.0 kg/m2 (including both values) at screening, and weight ≥ 50 kg;
• Normal glucose tolerance at screening \[3.9 mmol/L \< fasting blood glucose \< 6.1 mmol/L, and 2-hour post-glucose load blood glucose \< 7.8 mmol/L in the oral glucose tolerance test (OGTT)\]; normal insulin secretion function or abnormality without clinical significance as determined by the investigator \[confirmed by the insulin release test (IRT)\];
• Glycated hemoglobin ≤ 6.0% at screening;
• Agree to take effective contraceptive measures during the study period and within 6 months after the last dose and have no plan to donate sperm;
• Able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complete the trial, and voluntarily sign the informed consent form.

You may not qualify if:

• Known or suspected to be allergic to the investigational drug in this study;
• Have taken any drugs that affect insulin hypoglycemic effects within 28 days before screening (such as corticosteroids, diuretics, epinephrine, salbutamol, glucagon, thyroid hormones, etc.);
• Have a history of clinical significance as determined by the investigator at screening or before randomization, including diseases of the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, or any other disease that can significantly alter the absorption, metabolism, or elimination of drugs;
• Have a clear diagnosis of hyperglycemia or hypoglycemia within 3 months before screening;
• Have an increased risk of thrombosis at screening, including personal or family history of deep vein thrombosis;
• Have abnormal indicators with clinical significance at screening or before randomization: vital signs, physical examination, laboratory tests, chest X-ray, and 12-lead ECG as determined by the investigator;
• Have had a severe infection, trauma, or surgery within 4 weeks before screening;
• Have smoked more than 5 cigarettes per day within 3 months before screening, or have smoked within 48 hours before using the investigational drug or cannot stop using any tobacco products during the trial;
• Have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, or health supplements (except for regular vitamin supplements) within 2 weeks before screening;
• Have donated blood ≥ 400 ml or had any component blood donation within 3 months before screening, or have lost a total of ≥ 400 ml of blood for any reason, or have a history of blood transfusion or use of blood products;
• Have consumed more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 ml of beer, or 45 ml of spirits, or 150 ml of wine, and cannot abstain from alcohol within 48 hours before using the investigational drug;
• Have consumed excessive amounts of tea, coffee, and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 ml) daily within 3 months before screening;
• Have positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or Treponema pallidum antibodies;
• Have a history of drug abuse or drug use within 3 months before screening, or have positive results for alcohol tests or urine drug screening at screening. 15. Participants who have participated in other clinical trials and used investigational drugs or medical devices within the 3 months prior to screening;
• \. Participants with a weight change greater than 5% within the 3 months prior to screening \[(maximum weight within the 3 months prior to screening - minimum weight within the 3 months prior to screening) / minimum weight within the 3 months prior to screening × 100%, as self-reported by the participant\]; 17. Participants with any food allergies or special dietary requirements that prevent them from adhering to a uniform diet (such as intolerance to standard meal foods, lactose intolerance, etc.); 18. Participants who have experienced acute diseases during the screening period; 19. Participants with a history of fainting at the sight of needles or blood, who cannot tolerate venipuncture blood collection, or who have difficulty with blood collection; 20. Participants for whom the investigator deems there to be any circumstances that make them unsuitable for participation in the trial.

Sponsors & Collaborators

• Innovent Biologics (Suzhou) Co. Ltd.: lead

Study Sites (1)

Bishan Hospital of Chongqing

Chongqing, Chongqing Municipality, 402760, China

Location

MeSH Terms

Interventions

insulin icodec

Central Study Contacts

Shanyu Xu

CONTACT

+86-0512-69566088; shanyu.xu@innoventbio.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 21, 2026
• First Posted: May 15, 2026
• Study Start: May 8, 2026
• Primary Completion (Estimated): July 30, 2027
• Study Completion (Estimated): August 31, 2027
• Last Updated: May 15, 2026

Record last verified: 2026-05

Locations

CN (1)